NBC reports the July panel that backed the peptides included appointees with industry ties. Former FDA official Peter Lurie says the agency is turning a blind eye.
Recap by typeshit. Full story at NBC News.
Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
Gounder notes the policy requires no testing of finished vials or deadline for side effect reports, and public comments on the draft run through November 13.
Healio
Durrani tells Healio the move bypassed rulemaking and FDA scientists, and warns patients may wrongly read it as FDA approval while long-term data is missing.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
A Facebook share points to shifting drinking habits in pubs and bars as more people take GLP-1 medications, with the full story linked.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
Loading…